Capricor Therapeutics (CAPR)

P/S ratio as of January 2026 (TTM): 26.1

According to Capricor Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.47. At the end of 2025 the company had a P/S ratio of 29.1.

P/S ratio history for Capricor Therapeutics from 2002 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	29.1	1.3%
2024	28.7	380.68%
2023	5.98	-84.34%
2022	38.2	-86.78%
2021	289	27.81%
2020	226	3295.51%
2019	6.66	-13.53%
2018	7.70	-58.48%
2017	18.5	3.93%
2016	17.8	34.86%
2015	13.2	25.58%
2014	10.5
2013	N/A	-100%
2012	10.7	-32.86%
2011	16.0
2010	N/A
2009	N/A
2007	> 1000
2003	> 1000	91.37%
2002	920

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Cytokinetics CYTK	89.1	240.99%	🇺🇸 USA
Palatin Technologies PTN	2.96	-88.67%	🇺🇸 USA
Johnson & Johnson JNJ	5.41	-79.29%	🇺🇸 USA
Neurocrine Biosciences NBIX	5.27	-79.82%	🇺🇸 USA
Celldex Therapeutics CLDX	694	2,557.14%	🇺🇸 USA
Eterna Therapeutics ERNA	> 1000	35,954.26%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Capricor Therapeutics (CAPR)

P/S ratio as of January 2026 (TTM): 26.1